Product Pipeline
OriCell Therapeutics focuses on the unmet clinical needs for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer. It has developed several dozen pipelines for independently innovative cell drugs and monospecific/bispecific antibodies targeting solid tumors. Among them, six immune cell therapy products for tumors have been approved by the ethical committee of the hospital and entered the stage of exploratory clinical development. The Investigational New Drug (IND) application for four products has been initiated. The application materials for the first product will be submitted in the first quarter of 2022. The IND application for the other 3 products is currently underway.
CAR-T
OriCell Therapeutics Proprietary Pipeline Development
OriCell Therapeutics External Co-Development
Programs
Antibody
candidate
Enabling
CAR-T
OriCell Therapeutics Proprietary Pipeline Development
OriCell Therapeutics External Co-Development
Indication: HCC
IP:Global
Indication: R/RMM
IP:Global
Indication: R/RMM
IP:Global
Indication: Solid Tumor
IP:Global
Indication: Solid Tumor
IP:Global
Indication: Solid Tumor
IP:Global
Indication: Solid Tumor
IP:Global
Antibody
Target: PD-L1/4-1BB
Indication: Solid tumor
IP:Global
Target: 4-1BB
Indication: Solid tumor
IP:Global
Target: PD-L1
Indication: Solid tumor
IP:Global
Target: PVRIG
Indication: Solid Tumor
IP:China
Target: TIGIT
Indication: Solid tumor
IP:Global
Target: PD-L1/TIGIT
Indication: Solid tumor
IP:Global
Target: PD-L1/CLDN 18.2
Indication: Solid tumor
IP:Global
Target: 4-1BB/CLDN 18.2
Indication: Solid tumor
IP:Global
Target: CD73/CD39
Indication: Solid Tumor
IP: